Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel
Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel
About this item
Full title
Author / Creator
Publisher
Germany: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Germany: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Nab‐paclitaxel (Abraxane), an albumin‐bound solvent‐free paclitaxel (PTX) formulation that takes advantage of the endogenous albumin transport pathway, is the current gold standard for treatment of solid tumors with PTX. However, nab‐paclitaxel has several limitations, including complex manufacturing, immunogenicity, slow drug‐release, and a narrow...
Alternative Titles
Full title
Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_f24ec2aa4c224b659763f6bcc87b8c31
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f24ec2aa4c224b659763f6bcc87b8c31
Other Identifiers
ISSN
2688-4046
E-ISSN
2688-4046
DOI
10.1002/smsc.202400153
